Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127346871 | 12734687 | 1 | I | 20050926 | 20050927 | 20160913 | 20160913 | PER | US-ASTRAZENECA-2005BM02494 | ASTRAZENECA | 21605.00 | DY | F | Y | 76.70000 | KG | 20160913 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127346871 | 12734687 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | U | 9RE18M | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||
| 127346871 | 12734687 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | Y | U | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||||
| 127346871 | 12734687 | 3 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | U | U | 0 | 2 | MG | /wk | ||||||
| 127346871 | 12734687 | 4 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | U | U | 0 | 2 | MG | /wk | ||||||
| 127346871 | 12734687 | 5 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | U | U | 0 | 2 | MG | /wk | ||||||
| 127346871 | 12734687 | 6 | C | LANTUS | INSULIN GLARGINE | 1 | UNK | 0 | |||||||||||
| 127346871 | 12734687 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 1000.0MG UNKNOWN | 0 | 1000 | MG | |||||||||
| 127346871 | 12734687 | 8 | C | GLUCOTROL | GLIPIZIDE | 1 | 0 | 5 | MG | BID | |||||||||
| 127346871 | 12734687 | 9 | C | DYNACIRC | ISRADIPINE | 1 | UNK | 0 | |||||||||||
| 127346871 | 12734687 | 10 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | 0 | 40 | MG | QD | |||||||||
| 127346871 | 12734687 | 11 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 40 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127346871 | 12734687 | 1 | Type 2 diabetes mellitus |
| 127346871 | 12734687 | 2 | Type 2 diabetes mellitus |
| 127346871 | 12734687 | 3 | Insulin-requiring type 2 diabetes mellitus |
| 127346871 | 12734687 | 4 | Insulin-requiring type 2 diabetes mellitus |
| 127346871 | 12734687 | 5 | Insulin-requiring type 2 diabetes mellitus |
| 127346871 | 12734687 | 6 | Type 2 diabetes mellitus |
| 127346871 | 12734687 | 7 | Type 2 diabetes mellitus |
| 127346871 | 12734687 | 8 | Type 2 diabetes mellitus |
| 127346871 | 12734687 | 10 | Blood pressure abnormal |
| 127346871 | 12734687 | 11 | Blood pressure abnormal |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127346871 | 12734687 | Amnesia | |
| 127346871 | 12734687 | Blood glucose increased | |
| 127346871 | 12734687 | Diabetes mellitus inadequate control | |
| 127346871 | 12734687 | Injection site nodule | |
| 127346871 | 12734687 | Insomnia | |
| 127346871 | 12734687 | Nausea | |
| 127346871 | 12734687 | Product quality issue | |
| 127346871 | 12734687 | Stress | |
| 127346871 | 12734687 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127346871 | 12734687 | 1 | 20050926 | 0 | ||
| 127346871 | 12734687 | 2 | 2010 | 2012 | 0 | |
| 127346871 | 12734687 | 3 | 2013 | 2014 | 0 | |
| 127346871 | 12734687 | 4 | 20160804 | 0 | ||
| 127346871 | 12734687 | 6 | 20050925 | 0 |